Psychopharmacology and Psychiatry Updates Cariprazine for Bipolar Illness in the Elderly: What the Data Show
Mar 22, 2026
Kristin Raj, psychiatrist and psychopharmacology faculty contributor, reviews clinical evidence on cariprazine for bipolar disorder in older adults. She discusses why studying elders matters. Topics include pharmacology and approvals, pooled trial design, efficacy for depression and mania across ages, dosing recommendations, safety and tolerability, and monitoring for akathisia and motor side effects.
AI Snips
Chapters
Transcript
Episode notes
Cariprazine Works Similarly In Older Adults For Depression
- Cariprazine shows similar efficacy in older (≥50) and younger adults for bipolar I depression when using recommended doses.
- Pooled 1.5–3 mg/day improved depression in older adults, though individual dose groups lacked power.
Stick To 3–6 Mg For Mania In Older Patients
- Use 3–6 mg/day of cariprazine for acute mania or mixed episodes in older adults and avoid routinely escalating to 9–12 mg/day.
- Higher 9–12 mg doses did not outperform placebo in older patients and had higher discontinuation rates.
Higher Mania Doses Raise Discontinuation In Elders
- Overall tolerability of cariprazine was similar across age groups in depression trials, but discontinuations rose at higher mania doses in older adults.
- Stopping rates were numerically higher for 9–12 mg/day in the older group.